China's NMPA — formerly CFDA — is the regulatory authority for the world's second-largest medical device market. The registration system is complex, the timelines are long, and the requirements are unique to China. Our database indexes 40,000+ cross-market relevant records, with a focus on Class II and III devices.
Search China registrations →The National Medical Products Administration (NMPA) — formerly known as the China Food and Drug Administration (CFDA) before its 2018 reorganization — oversees medical device registration across China. The regulatory framework is established under the Regulations for the Supervision and Administration of Medical Devices and associated implementation rules.
China's medical device market is the second largest globally, valued at approximately USD 45–50 billion annually and growing at roughly 8–10% per year. The domestic manufacturing sector is rapidly developing, with Chinese companies increasingly competitive across Class II and some Class III device categories. For foreign manufacturers, China remains a high-priority market, but the regulatory pathway is among the most demanding in the world.
A note on our coverage: NMPA's full registry contains hundreds of thousands of registrations, including a very large number of purely domestic products. Our database focuses on the cross-market relevant subset — particularly foreign-origin devices and devices registered in multiple Asian markets — where Meridian Trace provides comparative intelligence value. Our 40,000+ China records are not the full NMPA registry.
NMPA uses a three-class system — Class I (lowest risk), Class II (moderate risk), Class III (highest risk). Unlike ASEAN's A/B/C/D system or Japan's four-class system, China's three tiers encompass a very wide range within Class III, which covers everything from coronary stents to certain implantable oncology devices.
| Class | Risk Level | Filing Authority | Examples |
|---|---|---|---|
| Class I | Low | Provincial NMPA (filing, not approval) | Bandages, non-powered instruments, basic examination tools |
| Class II | Moderate | Provincial NMPA (approval) | Syringes, X-ray equipment, powered wheelchairs, most IVD kits |
| Class III | High | National NMPA (approval) | Implantable cardiac devices, drug-eluting stents, high-risk IVDs |
One of China's most important regulatory features: the filing authority differs by device class. Class I devices file with local provincial authorities — a relatively streamlined process. Class II and Class III national registrations go through NMPA centrally, with Class III requiring national-level review.
This split has practical implications. Class II timelines at the provincial level can vary significantly by province — some provinces have built reputations for faster processing. Class III national registrations are uniform in process but notoriously slow, with realistic timelines of 3–5 years for novel high-risk devices.
Foreign medical device manufacturers cannot directly hold NMPA registrations. Registration must be held by a Chinese legal entity — either a wholly foreign-owned enterprise (WFOE), a joint venture, or a local Chinese company that is authorized to distribute the device. Unlike Japan (where the MAH is always a separate Japanese company), China allows foreign manufacturers to use their own Chinese WFOE as the registration holder, which provides more control.
This structural requirement means that due diligence on China registrations needs to account for the local entity that holds the registration — not just the OEM. In our database, we distinguish between the registration holder entity and the underlying manufacturer where we can identify this relationship.
China has been progressively tightening requirements for local clinical evidence. For Class III devices without a substantial history in China, NMPA increasingly expects clinical trials conducted in China with Chinese patients, conducted at NMPA-recognized clinical trial sites. This requirement is a major cost and timeline driver for foreign Class III registrations. Recent reforms have created some pathways for accepting overseas clinical data under specific conditions, but local clinical work remains the norm for novel high-risk devices.
Our China coverage is strongest for Class II and Class III devices with international cross-market presence. You can search by manufacturer name (including Chinese subsidiary names where we have them), device type, and registration number. Comparing a company's China NMPA registrations against their PMDA (Japan) or MFDS (Korea) registrations often reveals strategic market prioritization choices that are useful intelligence.
40,000+ cross-market relevant records. 50 free searches per month. No Chinese-language portal navigation.
40,000+ indexed records. Understand who's registered in China and what device categories they cover — without navigating Chinese-language government portals.